graft-versus-host disease

[Bone Marrow Transplantation] Researchers analyzed the outcome of 65 patients reported to the registry of the European Working Group of myelodysplastic syndrome in childhood carrying a germline GATA2 mutation who had undergone hematopoietic stem cell transplantation.

[Scientific Reports] Investigators demonstrated that, in an in vitro setting, MAPC cells increase Treg frequencies by promoting Treg proliferation and CD4+ T cell differentiation into Tregs.

[Synthetic Biologics, Inc.] Synthetic Biologics, Inc., a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases, announced that patient dosing and observation has been completed in its Phase I clinical trial of SYN-020 intestinal alkaline phosphatase.

[Bone Marrow Transplantation] Mice were followed for xenogeneic graft-versus-host disease score and survival. Human T-cell engraftment and as well as human T-cell subtypes were monitored in blood on days 14, 21, and 28 after transplantation.

[Scientific Reports] Researchers investigated the effects of reducing the dose of posttransplantation cyclophosphamide (PTCy) followed by α-galactosylceramide, a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect.

[Journal of Clinical Oncology] 120 patients with de novo acute myeloid leukemia received either romyelocel-L infusion on day nine with granulocyte colony-stimulating factor (G-CSF) starting daily on day fourteen (treatment group) or G-CSF daily alone on day fourteen (control) until absolute neutrophil count recovery to 500/µL.